Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
The findings span intravenous treatment in cancer models and survival observations in patients receiving a rectal proenzyme formulation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Propanc Biopharma (PPCB) announced publication of a peer-reviewed pilot study evaluating PRP in pancreatic and ovarian cancer models and reporting patient survival observations.
Published in Scientific Reports, the study evaluated trypsinogen and chymotrypsinogen A at a 1:6 ratio. Daily intravenous PRP reduced mean tumor weight by 85.9% at the higher dose in a pancreatic cancer model and approximately 50% across two doses in an ovarian cancer model, with no treatment-related adverse clinical events. Separately, 46 patients with advanced cancers received a rectal proenzyme formulation through the UK Specials Scheme. Mean survival was 9.0 months versus mean expected survival of 5.6 months; 19 patients exceeded predicted life expectancy. No severe or serious adverse events related to rectal administration, hematologic toxicity, or allergic reactions were observed.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointRectal-formulation cohort mean survival was 9.0 months versus 5.6 months expected across 46 patients (p < 0.05).
- Minor pointPancreatic cancer model mean tumor weight fell 85.9% with daily intravenous PRP at the higher dose.
- Minor pointOvarian cancer model tumor-weight inhibition was approximately 50% across two PRP dose levels.
- Minor pointPatients exceeding predicted life expectancy numbered 19 of 46 (41.3%) in the rectal-formulation cohort.
- Minor pointOrthotopic model treatment was well tolerated, with no treatment-related adverse clinical events.
8 minor points
- Minor pointRectal-formulation cohort showed no severe or serious administration-related adverse events, hematologic toxicity, or allergic reactions.
- Minor pointGrowth inhibition across 24 human cancer cell lines was synergistic at the 1:6 ratio relative to other ratios.
- Minor pointPRP reduced bFGF-driven fibrous capsule formation by 57% versus induction controls in the AngioChamber assay.
- Minor pointPRP dose-dependently blocked tube formation by human umbilical vein endothelial cells without affecting viability.
- Minor pointPRP inhibited cell migration in pancreatic, ovarian, melanoma and colon cell-line assays.
- Minor pointPRP produced near-complete, dose-dependent invasion blockade through Matrigel in pancreatic and colon cancer cells.
- Minor pointPancreatic and ovarian cells showed increased E-cadherin and decreased N-cadherin, Slug and vimentin, markers of cell identity.
- Minor pointImmunofluorescence confirmed increased membrane localization of E-cadherin and β-catenin.
Negative
- None.
Details
Market Reaction – PPCB
On Oct 14, the day this news came out, the latest delayed price for PPCB is 1.26% above the previous close. Our momentum scanner has recorded 11 alerts for this stock so far that day. The latest delayed price is $0.42. Relative volume is exceptionally heavy at 5.4x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- PRP formulation ratio
- 1:6
- Trypsinogen and chymotrypsinogen A combination
- Cancer cell lines
- 24
- Evaluated for growth inhibition across human cancer cell lines
- Fibrous capsule reduction
- 57%
- In vivo AngioChamber assay versus induction controls
- Mean tumor-weight reduction
- 85.9%
- Higher dose in a syngeneic orthotopic pancreatic model
- Tumor-weight inhibition
- ~50%
- Orthotopic ovarian model across two dose levels
- Patients in UK Specials cohort
- 46 patients
- Advanced cancers treated with a rectal proenzyme formulation
- Patients surviving longer than predicted
- 19 patients (41.3%)
- UK Specials cohort
- Mean survival
- 9.0 months versus 5.6 months (p < 0.05)
- Observed versus mean expected survival across the cohort
Historical Context
-
Reported PRP pancreatic-model tumor inhibition and survival benefit; outlined a planned Phase 1b study.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
angiogenesis medical
epithelial-to-mesenchymal transition medical
orthotopic medical
syngeneic medical
proenzymes medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Scientific Reports Paper Shows Synergistic Trypsinogen/Chymotrypsinogen A Combination (1:6) Inhibits Angiogenesis, Migration, Invasion and EMT While Delivering Significant Tumor Reduction in Orthotopic Models and Encouraging Survival Signals in Advanced Patients
MELBOURNE, Australia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced the publication of a peer-reviewed pilot study in Scientific Reports (Nature Publishing Group) titled “A formulation of pancreatic pro-enzymes provides potent anti-tumor efficacy: a pilot study focused on pancreatic and ovarian cancer.”
The study evaluates PRP, the Company’s proprietary fixed-ratio combination of the pancreatic proenzymes Trypsinogen and Chymotrypsinogen A (1:6). Across 24 human cancer cell lines, the 1:6 ratio demonstrated synergistic growth inhibition relative to other ratios. In summary:
- Anti-angiogenic activity: PRP dose-dependently blocked tube formation by human umbilical vein endothelial cells without affecting viability. In the in vivo AngioChamber™ assay, PRP reduced bFGF-driven fibrous capsule formation by
57% versus induction controls. - Anti-metastatic effects: PRP significantly inhibited cell migration in wound-healing assays (pancreatic, ovarian, melanoma and colon lines) and produced near-complete, dose-dependent blockade of invasion through Matrigel in pancreatic and colon cancer cells.
- EMT reversal: In BxPC3 pancreatic and A2780 ovarian cells, PRP increased epithelial marker E-cadherin while decreasing mesenchymal markers N-cadherin, Slug and vimentin. Immunofluorescence confirmed increased membrane localization of E-cadherin and β-catenin.
- Orthotopic efficacy: Daily intravenous PRP produced an
85.9% reduction in mean tumor weight in a syngeneic orthotopic pancreatic (Pan02) model at the higher dose and ~50% tumor-weight inhibition in an orthotopic ovarian (A2780) model across two dose levels. Treatment was well tolerated with no treatment-related adverse clinical events. - Clinical signals via UK Specials Scheme: In 46 patients with advanced, mostly metastatic cancers of various origins treated with a rectal proenzyme formulation, 19 patients (
41.3% ) survived longer than predicted life expectancy. Across the cohort, mean survival was 9.0 months versus a mean expected survival of 5.6 months (p < 0.05). No severe or serious adverse events related to rectal administration, hematologic toxicity, or allergic reactions were observed.
“The data published in Scientific Reports provide clear evidence that our synergistic PRP formulation can inhibit key drivers of tumor progression—angiogenesis, invasion and epithelial-to-mesenchymal transition—while delivering meaningful tumor growth suppression in relevant orthotopic models,” said Dr. Ralf Brandt, Propanc’s Research and Development Director. “The encouraging survival extension observed in the UK Specials program, together with the favorable tolerability profile, supports continued development of PRP as a differentiated, non-cytotoxic approach for patients with advanced pancreatic adenocarcinoma and epithelial ovarian cancer.”
PRP is designed as a long-term therapy to reduce the risk of tumor recurrence and metastasis—the primary cause of death in solid tumors. The Company’s initial target indications include pancreatic, ovarian and refractory prostate cancers, areas of high unmet need with limited durable treatment options.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What tumor reductions did Propanc Biopharma report for PRP in pancreatic and ovarian cancer models?
Daily intravenous PRP reduced mean tumor weight by 85.9% at the higher dose in the pancreatic model and produced approximately 50% tumor-weight inhibition across two doses in the ovarian model. These were orthotopic models, with tumors located in the corresponding organ, rather than patient tumor-response results.
What patient survival findings did Propanc Biopharma report in the pilot study?
Among 46 patients receiving a rectal proenzyme formulation through the UK Specials Scheme, mean survival was 9.0 months versus mean expected survival of 5.6 months (p < 0.05). The patients had advanced, mostly metastatic cancers of various origins; 19 patients (41.3%) survived longer than predicted life expectancy.